Skip to main content
. 2018 Oct 15;123:268–276. doi: 10.1016/j.ejps.2018.07.048

Table 1.

Composition of MLVs containing DOPE-TLR7a conjugate, TDB and DOPE.

MLV composition TDB w%/v% (μM) DOPE-TLR7a agonist w%/v% (μM) DOPE w%/v% (μM)
0% DOPE-TLR7a − TDB 0 (0) 0 (0) 20 (336)
0% DOPE-TLR7a + TDB 20 (250) 0 (0) 20 (336)
1% DOPE-TLR7a − TDB 0 (0) 1 (11.5) 19 (320)
20% DOPE-TLR7a − TDB 0 (0) 20 (230) 0 (0)
20% DOPE-TLR7a + TDB 20 (250) 20 (230) 0 (0)